Zydus Cadila

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy

The trials, which will commence in December, will be conducted on 250 patients across 20-25 centres in India, according to the filing.

PM's visit to Serum Institute: Here's why Uddhav Thackeray did not accompany Narendra Modi in Pune

PM's visit to Serum Institute: Here's why Uddhav Thackeray did not accompany Narendra Modi in Pune

Prime Minister Narendra Modi was on his three-city visit on Saturday to review coronavirus vaccine development work. Three major pharma p...Read More

PM Modi's visit has encouraged us in doing more, doing fast: Zydus Cadila chairperson

PM Modi's visit has encouraged us in doing more, doing fast: Zydus Cadila chairperson

"The scientists, all 18,000 of them and 25,000 plus Ziduns are continuously thriving and working for providing safe and efficacious vacci...Read More

Covishield, Covaxin & ZyCov-D top COVID-19 vaccine contenders. When will India get a vaccine?

Covishield, Covaxin & ZyCov-D top COVID-19 vaccine contenders. When will India get a vaccine?

In India, top contenders are Covishield, Covaxin and ZyCov-D. And, there is a new hope that India can get a vaccine soon. But, who will s...Read More

ICMR plans to launch indigenous COVID-19 vaccine by mid-August; experts remain skeptical

ICMR plans to launch indigenous COVID-19 vaccine by mid-August; experts remain skeptical

India's apex medical body ICMR said Friday that it aims to launch the world's first COVID-19 vaccine, the indigenously developed Covaxin,...Read More

Zydus Cadila's vaccine for COVID-19 completes pre-clinical development, to initiate human clinical trials

Zydus Cadila's vaccine for COVID-19 completes pre-clinical development, to initiate human clinical trials

Ahmedabad: Healthcare major Zydus Cadila said on Friday its plasmid DNA vaccine candidate for COVID-19 (ZyCoV-D) developed indigenously a...Read More

COVID-19 drug: After Zydus Cadila and Jubilant Life, Dr. Reddy's signs licensing agreement with Gilead Sciences for Remdesivir

COVID-19 drug: After Zydus Cadila and Jubilant Life, Dr. Reddy's signs licensing agreement with Gilead Sciences for Remdesivir

Dr. Reddy's Laboratories has entered into a non-exclusive licensing agreement with American-based biopharmaceutical company, Gilead Scien...Read More

Daily production capacity of hydroxychloroquine is enough for current demand: Sudarshan Jain

Daily production capacity of hydroxychloroquine is enough for current demand: Sudarshan Jain

Many countries around the world are trying to get access to hydroxychloroquine, an anti-malarial drug, which is largely produced in India...Read More

Zydus Cadila boosts Hydroxychloroquine production 10 times to battle coronavirus

Zydus Cadila boosts Hydroxychloroquine production 10 times to battle coronavirus

India is the biggest manufacturer of hydroxychloroquine, the anti-malarial drug that is being touted as 'game-changer' in the fight again...Read More

placeholder

Cadila profit at Rs 389 cr; to raise up to Rs 18,500 cr

New Delhi : Zydus Cadila group firm Cadila Healthcare reported a 10.93 % rise in net profit to Rs 388.7 crore for the March quarter and a...Read More

placeholder

Zydus Cadila buys select animal health brands of Zoetis

New Delhi : Zydus Cadila has expanded its animal health business with the acquisition of some select brands and a Haridwar-based manufact...Read More

placeholder

Zydus Cadila Launches Biosimilar Of Abbvie’s Humira

New Delhi : Drug firm Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much ...Read More

Free Press Journal

www.freepressjournal.in